The GH/IGF-1 Axis in Alzheimer's Disease: A Treatable Hormonal Factor in Dementia

GH and IGF-1 deficiency are associated with Alzheimer's disease, with evidence that restoring this axis improves cognitive function — positioning GH secretagogues as potential therapeutic agents for neurodegeneration.

Gómez, José Manuel·Endocrine·2008·Moderate EvidenceReview
RPEP-01349ReviewModerate Evidence2008RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Review
Evidence
Moderate Evidence
Sample
Not reported

What This Study Found

GH/IGF-1 axis decline correlates with Alzheimer's disease progression, with IGF-1 supporting neuronal survival, beta-amyloid clearance, and synaptic function — GH secretagogues that restore this axis may offer neuroprotective therapeutic benefit for dementia.

Key Numbers

How They Did This

review study.

Why This Research Matters

Relevant for hormone-optimization, neuroprotection, anti-aging.

The Bigger Picture

Advances peptide research.

What This Study Doesn't Tell Us

See abstract.

Questions This Raises

  • ?Further research needed.
  • ?Clinical translation to evaluate.

Trust & Context

Key Stat:
Key finding GH/IGF-1 axis decline correlates with Alzheimer's disease progression, with IGF-1 supporting neuronal survival, beta-amyloid clearance, and synaptic f
Evidence Grade:
moderate evidence.
Study Age:
Published in 2008.
Original Title:
Growth hormone and insulin-like growth factor-I as an endocrine axis in Alzheimer's disease.
Published In:
Endocrine, metabolic & immune disorders drug targets, 8(2), 143-51 (2008)
Database ID:
RPEP-01349

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study

Summarizes existing research on a topic.

What do these levels mean? →

Frequently Asked Questions

What was studied?

The GH/IGF-1 Axis in Alzheimer's Disease: A Treatable Hormonal Factor in Dementia

What was found?

GH and IGF-1 deficiency are associated with Alzheimer's disease, with evidence that restoring this axis improves cognitive function — positioning GH secretagogues as potential therapeutic agents for neurodegeneration.

Read More on RethinkPeptides

Cite This Study

RPEP-01349·https://rethinkpeptides.com/research/RPEP-01349

APA

Gómez, José Manuel. (2008). Growth hormone and insulin-like growth factor-I as an endocrine axis in Alzheimer's disease.. Endocrine, metabolic & immune disorders drug targets, 8(2), 143-51.

MLA

Gómez, José Manuel. "Growth hormone and insulin-like growth factor-I as an endocrine axis in Alzheimer's disease.." Endocrine, 2008.

RethinkPeptides

RethinkPeptides Research Database. "Growth hormone and insulin-like growth factor-I as an endocr..." RPEP-01349. Retrieved from https://rethinkpeptides.com/research/gomez-2008-growth-hormone-and-insulinlike

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.